ReviewCureus2025
Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, is recognized for its effectiveness in regulating glucose levels and promoting weight loss. This systematic review aims to evaluate the current evidence on the impact of tirzepatide on low-density lipoprotein (LDL) cholesterol levels in adult patients (i.e., individuals 18 years and older). A comprehensive search was conducted in the PubMed, EMBASE, and Web of Science databases through June 26, 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies included randomized controlled trials and observational studies in adults that reported LDL levels before and after receiving tirzepatide. The quality assessment was done using the Risk of Bias 2 tool (RoB 2, Cochrane Collaboration, London, UK) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I). This review found that high doses of tirzepatide were associated with moderate reductions in LDL cholesterol levels, accompanied by a 19% reduction and improvements in LDL particle size. However, the findings revealed heterogeneity, with younger individuals (i.e., those 64 years and younger) exhibiting larger reductions in LDL levels compared to older individuals (i.e., those 65 years and older). Observational studies also reported heterogeneous results, limited by confounding factors and co-interventions. Overall, tirzepatide may decrease LDL cholesterol and improve its lipid profile characteristics, especially at high doses (15 mg) and in individuals with metabolic risk factors; however, variability across studies and short follow-up periods limits the ability to draw definitive conclusions. Further research is needed to establish the role of tirzepatide in controlling LDL levels and reducing cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.